# Echo IQ pivots to AI payment codes after US setback as Artrya and Dorsavi gain US momentum

> Echo IQ CPT code bid stalls; Artrya adds major heart hospital; Dorsavi gains PT traction. ECS turns cash-flow positive; TrivarX, PainChek await news.

- Type: AI news
- Page: https://completeaitraining.com/news/echo-iq-pivots-to-ai-payment-codes-after-us-setback-as/
- Published: 2025-10-08
- Updated: 2025-10-08
- Author: Jeroen Erne
- Jobs: Healthcare
- Reading time: 2 min

### Health AI's Path to Payment: Setbacks and Progress in the US Market

The journey for new medical technology in the United States is rarely a straight line, especially when it involves artificial intelligence. Recent events highlight the regulatory hurdles and market wins shaping the future of AI in healthcare.

#### Echo IQ Faces Reimbursement Setback, Pivots to Plan B

Heart disease detection company **Echo IQ (ASX:EIQ)** experienced a "frustrating" rejection for a Category III Current Procedural Technology (CPT) code in the US. The code was for its AI-powered aortic stenosis tool, **Echosolv AS**, which analyzes echocardiograms to produce a rapid risk assessment.

CPT codes are essential. They create a standard language for medical services, enabling efficient payment from insurers and Medicare. Without a specific code, securing reimbursement becomes a significant challenge.

The company has a multi-pronged response. It is eyeing new AI-specific codes proposed for next year, which are designed for services that augment a physician's work. Echo IQ is also considering an appeal with the [American Medical Association (AMA)](https://www.ama-assn.org/?ref=completeaitraining.com) and will use an existing miscellaneous code in the interim.

CEO Dustin Haines called the decision a bump in the road, expressing confidence that engagement with regulators will pay off as new AI frameworks develop. The company continues to advance its broader heart failure tool, **Echosolv HF**, with a validation study at the Mayo Clinic nearing completion.

#### Artrya Secures Major US Hospital for Plaque Trial

In contrast, **Artrya (ASX:AYA)** has enlisted a large specialist heart hospital for its Sapphire clinical trial. The Huntsville Hospital Heart Centre in Alabama will help test **Salix**, Artrya's AI platform for assessing coronary artery plaque from CT scans.

Huntsville is a high-volume center, handling over a million outpatient procedures annually. This partnership adds significant weight to the trial, which is scheduled to begin in early 2026. High-risk plaque is a critical indicator of heart disease that current methods often miss.

Artrya is well-funded after a recent $80 million capital raise. The company already has FDA approval for two modules of its Salix platform and expects approval for a third, Salix Coronary Flow, early next year.

#### Dorsavi Gains Traction in US Physical Therapy

Movement analysis specialist **Dorsavi (ASX:DVL)** is seeing strong adoption in the American physical therapy (PT) market. A recent training event for its **Vimove** product resulted in a 90% conversion rate, with 27 of 30 attending clinics signing on.

This is a sharp increase from the company's typical 4-5 new subscriptions per month. Vimove provides objective, report-style motion analysis for surgeons and patients. With a US market of over 66,000 PT clinics, Dorsavi sees an inflection point for significant growth and is planning more training events across the country.

#### Other Health Tech Updates

- **ECS Botanics (ASX:ECS):** The medical cannabis producer achieved positive cash flow in the September quarter. It is countering a market flooded with lower-quality imports by emphasizing its organic certification and Good Manufacturing Practice standards while expanding into Europe.
- **TrivarX (ASX:TRI):** This mental health company is in a trading halt pending news on a clinical trial, a material acquisition, and a potential capital raise. The trial is evaluating an ECG algorithm for detecting depression in veterans.
- **PainChek (ASX:PCK):** Shares are paused as the company awaits an FDA decision on its digital pain management application for the US market.

---

This is the Markdown form of https://completeaitraining.com/news/echo-iq-pivots-to-ai-payment-codes-after-us-setback-as/. The whole site is mapped at https://completeaitraining.com/llms.txt.
